Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service prostatectomy & nephrectomy cases in Nebraska: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (203 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 14 | 435 | 18% |
| 2020 | 11 | 446 | 22% |
| 2021 | 8 | 447 | 27% |
Robotic radical prostatectomy and laparoscopic nephrectomy. Professional codes (what the surgeon bills): CPT 55866, 50543, 50545, 50546, 50548; the hospital bills MS-DRG 707, 708, 656, 657, 658.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Nebraska; 7 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 35 | 1,512−0.1%/yr | −0.1%/yr | 5.81.1× | 12% | 1,880 in 2030+3.7%/yr |
| BPH procedures |
Prostatectomy & nephrectomy in every state, and its device makers · Every procedure market in Nebraska · Every state · Compare with Ohio
| 2024 |
| 452 |
| 37% |
| 2025 est. | ≈ 440 | – |
| 2026 est. | ≈ 460 | – |
| 2022 | 13 | 459 | 31% |
| 2023 | 10 | 458 | 35% |
| 2024 | 9 | 452 | 37% |
| 2025 from claims | – | 441 357–518 | 37% |
| 2026 forecast | – | 458 359–575 | 37% |
| 2027 forecast | – | 472 350–623 | 37% |
| 2028 forecast | – | 486 344–671 | 38% |
| 2029 forecast | – | 500 340–717 | 38% |
| 2030 forecast | – | 515 338–765 | 38% |
In 2025, 28% inpatient hospital, 72% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~460 | ~120 | ~330 |
| 2027 · ~470 | ~120 | ~350 |
| 2028 · ~490 | ~130 | ~360 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 26% (28% in 2025), hospital outpatient about 74% (72% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| 1,462−0.6%/yr |
| −0.6%/yr |
| 1.1 |
| 0% |
| 1,710 in 2030+2.7%/yr |
| Indiana | 17 | 989+0.3%/yr | +0.3%/yr | 1.5 | 0% | 1,570 in 2030+8%/yr |
| Michigan | 10 | 897−4.5%/yr | −4.5%/yr | 1.2 | 0% | 1,150 in 2030+4.2%/yr |
| Missouri | 11 | 798−1.8%/yr | −1.8%/yr | 1.4 | 0% | 980 in 2030+3.5%/yr |
| Minnesota | 10 | 773+1.1%/yr | +1.1%/yr | 1.9 | 0% | 1,410 in 2030+11%/yr |
| Wisconsin | 15 | 741−1.7%/yr | −1.7%/yr | 1.5 | 0% | 1,000 in 2030+5.1%/yr |
| Kansas | 10 | 583−1.8%/yr | −1.8%/yr | 1.5 | 0% | 720 in 2030+3.6%/yr |
| Iowa | 8 | 457+1.6%/yr | +1.6%/yr | 1.1 | 0% | 470 in 2030+0.6%/yr |
| South Dakota | 8 | 299+3.3%/yr | +3.3%/yr | 2.5 | 0% | 560 in 2030+11%/yr |
| 20 |
| 1,469−17%/yr |
| −17%/yr |
| 5.61.2× |
| 29% |
| 1,250 in 2030−2.7%/yr |
| Incontinence, prolapse & sacral neuromodulation | 12 | 849−2%/yr | −2%/yr | 3.21.5× | 24% | 1,020 in 2030+3.1%/yr |
| Hysterectomy, hysteroscopy & ablation | 4 | 529−3.8%/yr | −3.8%/yr | 2.20.7× | 9% | 650 in 2030+3.6%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Intuitive Surgical leads with 100% of company spending on these surgeons in 2025, level with 2024.
In 2025, 2 companies reported engagement with Nebraska’s surgeons worth $67K in consulting, speaking, meals and travel tied to these products, about $7,477 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 9 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.